肝细胞癌患者经动脉化疗栓塞术后的短暂细胞溶解
Transient Cytolysis after Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
作者信息
Rodríguez-Perálvarez Manuel
机构信息
Department of Hepatology and Liver Transplantation, Hospital Universitario Reina Sofía and IMIBIC, 14004 Córdoba, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 28029 Madrid, Spain.
出版信息
J Pers Med. 2022 Oct 6;12(10):1663. doi: 10.3390/jpm12101663.
Abstract
Transarterial chemoembolization (TACE) is a minimally invasive radiological procedure which consists of infusing a chemotherapeutic agent in the main arterial supplier of the liver tumor, usually emulsion-based doxorubicin, followed by the occlusion of the involved vessel with 100-500 micron-sized embolic particles [...].
摘要
经动脉化疗栓塞术（TACE）是一种微创放射学手术，该手术包括在肝肿瘤的主要动脉供血血管中注入化疗药物，通常是基于乳剂的阿霉素，然后用100 - 500微米大小的栓塞颗粒闭塞受累血管[……]
相似文献
1
Transient Cytolysis after Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.肝细胞癌患者经动脉化疗栓塞术后的短暂细胞溶解
J Pers Med. 2022 Oct 6;12(10):1663. doi: 10.3390/jpm12101663.
2
Impact of cytolysis following transarterial chemoembolization for hepatocellular carcinoma.经动脉化疗栓塞术治疗肝细胞癌后的细胞溶解作用的影响。
J Gastrointest Oncol. 2013 Mar;4(1):45-52. doi: 10.3978/j.issn.2078-6891.2012.061.
3
Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.经动脉化疗栓塞治疗肝细胞癌后肝动脉损伤：一项回顾性对照研究中药物洗脱微球与传统化疗栓塞的比较
Acta Radiol. 2017 Feb;58(2):131-139. doi: 10.1177/0284185116648501. Epub 2016 Jul 12.
4
[Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].多柔比星洗脱微球经动脉化疗栓塞术（DEB-TACE）与传统经动脉化疗栓塞术（TACE）治疗肝细胞癌的比较
Radiologia. 2011 May-Jun;53(3):246-53. doi: 10.1016/j.rx.2010.07.010. Epub 2011 Feb 4.
5
Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model.传统多柔比星经动脉栓塞化疗与载药栓塞经动脉化疗栓塞的比较：兔VX2肿瘤模型中的药物递送、药代动力学及治疗反应
Drug Deliv Transl Res. 2022 May;12(5):1105-1117. doi: 10.1007/s13346-021-00985-8. Epub 2021 Apr 16.
6
Sulfamethazine-based pH-sensitive hydrogels with potential application for transcatheter arterial chemoembolization therapy.基于磺胺甲噁唑的 pH 敏感水凝胶，具有经导管动脉化疗栓塞治疗的应用潜力。
Acta Biomater. 2016 Sep 1;41:253-63. doi: 10.1016/j.actbio.2016.05.018. Epub 2016 May 13.
7
Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review.经动脉化疗栓塞与不可切除肝细胞癌：一项叙述性综述
Cureus. 2022 Aug 26;14(8):e28439. doi: 10.7759/cureus.28439. eCollection 2022 Aug.
8
DEB TACE for Intermediate and advanced HCC - Initial Experience in a Brazilian Cancer Center.经动脉化疗栓塞术治疗中晚期肝癌——巴西一家癌症中心的初步经验
Cancer Imaging. 2017 Feb 6;17(1):5. doi: 10.1186/s40644-017-0108-6.
9
Visualization and Evaluation of Chemoembolization on a 3D Decellularized Organ Scaffold.三维去细胞化器官支架上的化疗栓塞的可视化和评估。
ACS Biomater Sci Eng. 2021 Dec 13;7(12):5642-5653. doi: 10.1021/acsbiomaterials.1c01005. Epub 2021 Nov 4.
10
Magnetic mesoporous embolic microspheres in transcatheter arterial chemoembolization for liver cancer.载药磁性介孔栓塞微球在肝癌经导管动脉化疗栓塞术中的应用
Acta Biomater. 2021 Aug;130:374-384. doi: 10.1016/j.actbio.2021.05.031. Epub 2021 May 31.
引用本文的文献
1
Therapy Response and Survival among Patients with Gynecologic Tumors Treated with Transarterial Chemoperfusion and Transarterial Chemoembolization.经动脉化学灌注化疗和经动脉化学栓塞化疗治疗妇科肿瘤患者的治疗反应和生存情况。
Medicina (Kaunas). 2024 Sep 27;60(10):1585. doi: 10.3390/medicina60101585.
2
Enumeration and Characterization of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.经动脉化疗栓塞术治疗的肝细胞癌患者循环肿瘤细胞的检测与鉴定。
Int J Mol Sci. 2023 Jan 29;24(3):2558. doi: 10.3390/ijms24032558.
本文引用的文献
1
Hepatocellular carcinoma.肝细胞癌
Lancet. 2022 Oct 15;400(10360):1345-1362. doi: 10.1016/S0140-6736(22)01200-4. Epub 2022 Sep 6.
2
ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization.ASARA，一种基于 Child-Pugh 分级的肝细胞癌患者经动脉化疗栓塞术的预测模型。
Hepatobiliary Pancreat Dis Int. 2023 Oct;22(5):490-497. doi: 10.1016/j.hbpd.2022.02.007. Epub 2022 Feb 25.
3
Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma.经动脉化学治疗肝癌的限制与可能性。
Int J Mol Sci. 2021 Dec 2;22(23):13051. doi: 10.3390/ijms222313051.
4
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.BCLC 策略用于预后预测和治疗推荐：2022 年更新版。
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.
5
TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma.TRANS-TACE：常规化疗栓塞术后短暂性高转氨酶血症在肝细胞癌中的预后作用
J Pers Med. 2021 Oct 17;11(10):1041. doi: 10.3390/jpm11101041.
6
Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy.肝细胞癌局部区域治疗后的免疫反应：辅助免疫治疗的可能作用
Pharmaceutics. 2021 Sep 2;13(9):1387. doi: 10.3390/pharmaceutics13091387.
7
A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function.基于肝功能的肝细胞癌经动脉化疗栓塞术的差异风险评估与决策模型
BMC Cancer. 2020 Jun 1;20(1):504. doi: 10.1186/s12885-020-06975-2.
8
Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE).mHAP-II 评分在经载药微球栓塞化疗（DEB-TACE）治疗的肝细胞癌患者中的真实世界预测性能。
Eur Radiol. 2020 Jul;30(7):3782-3792. doi: 10.1007/s00330-020-06734-8. Epub 2020 Mar 3.
9
Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma.mTOR 信号通路在肝细胞癌中的激活。
Int J Mol Sci. 2020 Feb 13;21(4):1266. doi: 10.3390/ijms21041266.
10
Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study.美国肝癌患者经动脉化疗栓塞术后肝功能变化：LiverT 研究。
BMC Cancer. 2019 Aug 13;19(1):795. doi: 10.1186/s12885-019-5989-2.
Zotero 插件